诺华公司为美国药品制造投资23B美元 以降低价格和避免关税 Novartis to invest $23B in U.S. drug manufacturing to cut prices and avoid tariffs.

Novartis CEO Vasant Narasimhan表示, 该公司将在五年内在美国投资230亿美元, 在当地制造关键药品, Novartis CEO Vasant Narasimhan said the company is investing $23 billion in the U.S. over five years to manufacture key drugs locally, aiming to reduce prices for American patients and avoid potential tariffs. 这项行动预计将在两年内取得显著进展,重点是在美国进行最后装载和包装,这有助于减轻欧盟和瑞士的进口关税。 The move, expected to yield significant progress within two years, focuses on final filling and packaging in the U.S., which could help mitigate import duties from the EU and Switzerland. 在药品价格不下降的情况下，将征收高达 250% 的关税的威胁中，诺华正在为多种贸易方案做准备，同时强调与美国政府的合作。 Amid threats of up to 250% tariffs if drug prices don’t drop, Novartis is preparing for multiple trade scenarios while emphasizing collaboration with the U.S. government. 该公司计划在自动化和扩大的教育方案的支持下,仅再雇用1 000至1 500名工人。 The company plans to hire only 1,000 to 1,500 additional workers, supported by automation and expanded education programs.